UPMC Hillman Cancer Center is exploring everything radiation treatment can treat, and the success has been life-changing for people.

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Researchers have identified a specific hormone produced by pancreatic beta cells as a direct driver of obesity-linked ...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

Scientists created an immunotherapy that tracks pancreatic cancer even after it spreads. The breakthrough treatment works in lab studies, though long-term safety in humans remains unknown.

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...

Bolstered Cash Position Expected to Capitalize the Company’s Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data ...

IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades.

A birthing room at the hospital has been named in her honour and now her sister is taking on a fundraising challenge ...